

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Applicants : David M. Stern, et al.
U.S. Serial No: 09/872,185
Filed : June 1, 2001
Page 3

Amendments to the claims:

This listing of the claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

- Claim 1 (withdrawn) A method for treating inflammation in a subject which comprises administering to the subject soluble receptor for advanced glycation endproduct (sRAGE) (SEQ ID NO:1) in an amount effective to treat inflammation in the subject.
- Claim 2 (withdrawn) A method for treating inflammation in a subject which comprises administering to the subject a polypeptide consisting essentially of the V-domain (SEQ ID NO:2) of receptor for advanced glycation endproduct (RAGE) in an amount effective to treat inflammation in the subject.
- Claim 3 (currently amended) A method for treating inflammation in a subject which comprises administering to the subject an agent selected from the group consisting of soluble receptor for advanced glycation endproduct (sRAGE), V-domain of sRAGE, or anti-RAGE antibody or anti-EN-RAGE F(ab')₂ fragment in an amount which inhibits the interaction between receptor for advanced glycation endproduct (RAGE) and either AGE or EN-RAGE,

Applicants : David M. Stern, et al.
U.S. Serial No: 09/872,185
Filed : June 1, 2001
Page 4

~~its ligand~~ thereby treating inflammation in the subject.

Claims 4-6 (canceled)

Claim 7 (currently amended) The method of claim 3 ~~any one of claims 1 to 3~~, wherein the subject is a mammal.

Claim 8 (original) The method of claim 7, wherein the mammal is a human.

Claim 9 (currently amended) The method of claim 3 ~~any one of claims 1 to 3~~, wherein the administration comprises intralesional, intraperitoneal, intramuscular or intravenous injection; infusion; liposome-mediated delivery; topical, nasal, oral, anal, ocular or otic delivery.

Claim 10 (original) The method of claim 3, wherein the agent is administered daily.

Claim 11 (currently amended) The method of claim 3 ~~any one of claims 1 to 3~~, wherein the amount comprises a dose of from about 200 ng/day/kg body weight to about 200,000 ng/day/kg body weight.

Claim 12 (currently amended) The method of claim 3 ~~any one of claims 1 to 3~~, wherein the inflammation is associated with a wound in the subject.

Applicants : David M. Stern, et al.
U.S. Serial No: 09/872,185
Filed : June 1, 2001
Page 5

Claim 13 (currently amended) The method of claim 3 ~~any one of claims 1 to 3~~, wherein the inflammation is associated with periodontal disease in the subject.

Claim 14 (withdrawn) The method of any one of claims 1 to 2, wherein the inflammation is associated with an autoimmune disease in the subject.

Claim 15 (withdrawn) The method of claim 14, wherein the autoimmune disease is multiple sclerosis or autoimmune encephalitis.

Claim 16 (currently amended) The method of claim 3 ~~any one of claims 1 to 3~~, wherein the inflammation is associated with delayed-type hypersensitivity of a subject.

Claim 17 (currently amended) The method of claim 3 ~~any one of claims 1 to 3~~, wherein the inflammation is associated with arthritis in a subject.

Claim 18 (original) The method of claim 17, wherein the arthritis comprises collagen-induced arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, arthritis due to Behchet's Syndrome, arthritis due to Sjogren's Syndrome, or arthritis induced by lupus.

Claims 19-25 (canceled)

Applicants : David M. Stern, et al.
U.S. Serial No: 09/872,185
Filed : June 1, 2001
Page 6

Amendments to The Drawings:

Please replace Figures 2, 3A, 3B, 5, 9, 11-16 and 18-22 with corrected Figures 2, 3A, 3B, 5, 9, 11-16 and 18-22.